Irvine, CA – February 3, 2026 – Johnson & Johnson is announcing new portfolio innovations in addition to compelling clinical evidence in atrial fibrillation (AFib) at the 31st Annual AF Symposium in Boston. Eleven accepted abstracts will be presented to spotlight recent updates to its Pulsed Field Ablation (PFA) and Ultrasound portfolios, underscoring its commitment to evidence‑driven innovation that elevates the standard of care for physicians and patients worldwide.
Building on Johnson & Johnson’s dedication to continuously evolve PFA technologies based on real-world learnings and our scientific expertise, the company is introducing the VARIPULSE Plus Platform. This platform update introduces automated irrigation flow to build procedural confidence and reinforce its well-established safety profile.i,ii The VARIPULSE Platform is the first PFA technology designed to streamline ablation and mapping through a single integrated workflow with the CARTO 3 System.1,iii,iv This combination offers enhanced precision, efficiency, and procedural reproducibility for physicians treating patients with AFib.v,vi,vii
Johnson & Johnson is also announcing the full commercial release of NUVISION NAV Ultrasound Catheter, the world’s first 4D intracardiac imaging catheter fully integrated with a 3D electroanatomical mapping system. Fully integrated with the CARTO 3 System, NUVISION NAV delivers real-time 4D intracardiac imaging designed to enhance anatomical visualization, support precise navigation and guide complex EP proceduresviii,ix with minimal catheter manipulation[2] and reduced fluoroscopy use.x,xi. As a global leader in cardiac imaging and electrophysiology, Johnson & Johnson is redefining the role of intracardiac ultrasound and setting a new standard for imaging-driven EP guidance.
“Evidence-based innovation is the foundation of how we advance arrhythmia care. The data and technology updates we are sharing at AF Symposium demonstrate how we are continuously strengthening our electrophysiology portfolio,” said Michael Bodner, Company Group Chair, Electrophysiology & Neurovascular, MedTech, Johnson & Johnson. “These technology advancements and upcoming iterations are built on our scientific foundation and will continue raising the bar for AFib ablation.”
Highlights of data being presented include:
Late-Breaking Presentation: Pulse Field Ablation with a Large-Tip Focal Catheter with 3D Mapping Integration: Early Outcomes from the Omny-AF Single-Arm Pilot Study. Friday, February 6. 5:30pm ET, Dr. Dinesh Sharma3
Poster Presentation: Reduced Neurovascular Events Following Workflow and Irrigation Adjustments with a Variable Loop PFA Catheter for Ablation of Atrial Fibrillation. AFS2026-57. Dr. Moussa Mansour4
Poster Presentation: Acute Safety Profile of Variable-Loop Circular Catheter Pulsed Field Ablation for Paroxysmal and Persistent Atrial Fibrillation in the REAL AF Registry. AFS2026-35. Dr. Mohammad Ali Jazayeri5
Poster Presentation: The Variable Loop Circular Catheter Safety Survey (VariSure) Early Results. AFS2026-76. Dr. Christopher Porterfield6
Poster Presentation: Irrigation Flow Optimization During Pulsed Field Ablation: Preclinical Insights with a Variable Loop Circular Catheter. AFS2026-102, Dr. Fengwei Zou7
Poster Presentation: 4D Intracardiac Echo with NUVISION™- versus transesophageal echocardiography - guidance for left atrial appendage occlusion. AFS2026-97. Dr. David Weisman8
In addition to data presentations, Johnson & Johnson will support a variety of educational programs, in-booth presentations and training opportunities for attendees. Experts will lead hands-on sessions powered by CARTO 3 System, the world’s leading cardiac mapping system.9 Participants will be able to experience the VARIPULSE Plus Platform’s new automated irrigation-flow control in addition to the next-generation NUVISION NAV Ultrasound Catheter in a simulation for concomitant procedures.
Cardiovascular Solutions from Johnson & Johnson MedTech
Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration, and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke. For more, visit biosensewebster.com.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in surgery, orthopaedics, vision, and cardiovascular solutions at https://thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to Collaborative Outcomes Registry for Evidence in Ventricular Arrhythmias. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
© Johnson & Johnson and its affiliates 2026. All rights reserved. US_ELP_THER_411613
Footnotes:
1 When compared to procedures that did not use navigation systems.
2 More flexibility in imaging acquisition compared to 2D ICE.
3 Dr. Sharma served as a study investigator and as a consultant for Johnson & Johnson. Dr. Sharma was not compensated for this authorship contribution.
4 Dr. Mansour served as a study investigator and as a consultant for Johnson & Johnson. Dr. Mansour was not compensated for this authorship contribution.
5 Dr. Jazayeri served as a study investigator and as a consultant for Johnson & Johnson. Dr. Jazayeri was not compensated for this authorship contribution.
6 Dr. Porterfield served as a study investigator and as a consultant for Johnson & Johnson. Dr. Porterfield was not compensated for this authorship contribution.
7 Dr. Zou served as a study investigator and as a consultant for Johnson & Johnson. Dr. Zou was not compensated for this authorship contribution.
8 Dr. Weisman served as a study investigator and as a consultant for Johnson & Johnson. Dr. Weisman was not compensated for this authorship contribution.
9 J&J MedTech US EP Market Dynamics. Source: DRG Clarivate. Data Latency: 8 weeks. Market Coverage: ~35% US Hospitals.
i Almorad A, Sebag FS, Brix Kronborg M, et al. Acute safety, effectiveness and procedural workflow for the pulsed field ablation variable loop circular catheter in AF procedures: a prospective, multicenter, post-market clinical trial. Presented at: European Society of Cardiology (ESC) Congress; September 1, 2025; Madrid, Spain.
ii Porterfield C, Krishnan K, Saleem M, Steckman D, Ebinger M, Gampa A, et al. Real-world safety profile of a multi-electrode variable loop pulsed-field ablation catheter. Presented at: Kansas City Heart Rhythm Symposium 2025; August 16 2025; Overland Park (Kansas City), KS.
iii Scherr D, Turagam MK, Maury P, et al. Repeat procedures after pulsed field ablation for atrial fibrillation: MANIFEST-REDO study. EP Europace. 2025;: euaf012. doi:10.1093/europace/euaf012.
iv Fink T, Sciacca V, Bannmann K, et al. First experience using a novel variable loop catheter for mapping and pulsed field ablation of atrial fibrillation. Pacing Clin Electrophysiol. 2025 May;48(5):471-479. doi:10.1111/pace.15177. Epub 2025 Mar 28. PMID:40153431; PMCID:PMC12063197
v Di Biase L, Marazzato J, Gomez T, et al. Application Repetition and Electrode-Tissue-Contact Results in Deeper Lesions Using a Pulsed-Field Ablation Circular Variable Loop Catheter. Europace. Published online August 16, 2024. Page 3, paragraph 2, Results Section
vi Duytschaever M, De Potter T, Grimaldi M, et al. Paroxysmal Atrial Fibrillation Ablation Using a Novel Variable-Loop Biphasic Pulsed Field Ablation Catheter Integrated With a 3-Dimensional Mapping System: 1-Year Outcomes of the Multicenter inspIRE Study. Circ Arrhythm Electrophysiol. 2023 Mar;16(3):e011780. Page 5, Column 1, paragraph 1
vii Reddy VY, Calkins H, Mansour M, et al. Pulsed field ablation to treat paroxysmal atrial fibrillation: safety and effectiveness in the admIRE pivotal trial. Circulation. Published online September 11, 2024. doi: 10.1161/CIRCULATIONAHA.124.070333.Page 5, paragraph 2, Procedural Data Section
viii NUVISION™ NAV Target Product Profile, TPP4-0673. 3_20_2023
ix NUVISION™ NAV Ultrasound Catheter Global Marketing Plan, WWMP405-0673 Rev A. 3_20_2023
x Hemam ME, Kuroki K, Schurmann PA, et al. Left atrial appendage closure with the Watchman device using intracardiac vs transesophageal echocardiography: Procedural and cost considerations. Heart Rhythm. 2019;16(3):334-342.
xi Anter E, Silverstein J, Tschabrunn CM, et al. Comparison of intracardiac echocardiography and transesophageal echocardiography for imaging of the right and left atrial appendages. Heart Rhythm. 2014;11(11):1890-1897. doi:10.1016/j.hrthm.2014.07.015.
Always verify catheter tip location using common clinical practice for real-time verification (inspection of IC signals, direct imaging guidance such as fluoroscopy or ultrasound, etc.) and consult the CARTO™ 3 System User Guide regarding recommendations for fluoroscopy use. Canpolat, U. et al (2020). State of Fluoroless Procedures in Cardiac Electrophysiology Practice. J Innov Cardiac Rhythm Management. 11(3), 4018–4029. Sommer, P. et al (2018) Safety profile of near-zero fluoroscopy atrial fibrillation ablation with non[1]fluoroscopic catheter visualization: experience from 1000 consecutive procedures, EP Europace, Volume 20, Issue 12, Pages 1952–1958.
Important information: Prior to use, refer to the instructions for use supplied with this device for indications, contraindications, side effects, warnings and precautions.
Caution: US law restricts this device to sale by or on the order of a physician.
Media Contacts:
Erin Farley
Efarley1@its.jnj.com
Majo Echeverria
MEchever@its.jnj.com